Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
$0.46
-2.3%
$0.43
$0.29
$1.43
$14.40M-0.03201,009 shs40,696 shs
IMAC Holdings, Inc. stock logo
BACK
IMAC
$3.87
-24.1%
$2.28
$1.22
$7.75
$4.45M0.25773,459 shs813,114 shs
IMAC Holdings, Inc. stock logo
IMAC
IMAC
$5.10
+46.1%
$2.29
$0.75
$1.65
$135.07M-0.88708,132 shs8.49 million shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.64
-0.5%
$1.28
$0.60
$5.24
$4.38M1.91940,638 shs58,357 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
+2.62%+14.63%+38.19%-20.34%-58.34%
IMAC Holdings, Inc. stock logo
BACK
IMAC
+46.55%+64.52%+112.50%+140.57%+17.32%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
+54.55%+43.66%+112.50%+141.71%+3,595.65%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
+0.87%-8.31%-58.72%-41.83%-85.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
N/AN/AN/AN/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/AN/AN/AN/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
N/AN/AN/AN/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
3.1589 of 5 stars
3.55.00.00.02.81.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
N/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
N/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
3.00
Buy$4.00528.14% Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
$97.15M0.15$0.25 per share1.87($0.60) per share-0.77
IMAC Holdings, Inc. stock logo
BACK
IMAC
$16.19M0.27N/AN/A($0.66) per share-5.86
IMAC Holdings, Inc. stock logo
IMAC
IMAC
$15.22M8.88N/AN/A$0.69 per share7.39
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.82M0.75N/AN/A$4.04 per share0.16

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
-$11.33MN/A0.00N/AN/AN/AN/A5/15/2024 (Estimated)
IMAC Holdings, Inc. stock logo
BACK
IMAC
-$9.42M-$14.04N/AN/A-176.22%-2,069.01%-162.93%5/17/2024 (Estimated)
IMAC Holdings, Inc. stock logo
IMAC
IMAC
-$10.54MN/A0.00N/AN/A-75.40%-52.17%-34.51%N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$6.34N/AN/A-181.87%-68.90%-24.74%5/20/2024 (Estimated)

Latest IMAC, BACK, AIH, and PTPI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/1/2024Q4 2023
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/A-$2.17-$2.17-$2.17N/A($0.36) million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
N/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/AN/AN/AN/AN/A
IMAC Holdings, Inc. stock logo
IMAC
IMAC
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
N/AN/AN/A
IMAC Holdings, Inc. stock logo
BACK
IMAC
N/A
0.60
0.60
IMAC Holdings, Inc. stock logo
IMAC
IMAC
0.01
1.27
1.27
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.57
1.89
1.74

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
2.13%
IMAC Holdings, Inc. stock logo
BACK
IMAC
5.84%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
24.27%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%

Insider Ownership

CompanyInsider Ownership
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
55.10%
IMAC Holdings, Inc. stock logo
BACK
IMAC
10.00%
IMAC Holdings, Inc. stock logo
IMAC
IMAC
10.00%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
36.38%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aesthetic Medical International Holdings Group Limited stock logo
AIH
Aesthetic Medical International Holdings Group
1,16731.35 million14.08 millionNot Optionable
IMAC Holdings, Inc. stock logo
BACK
IMAC
21.15 million1.03 millionNot Optionable
IMAC Holdings, Inc. stock logo
IMAC
IMAC
10626.49 million23.84 millionNot Optionable
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
216.88 million4.38 millionNot Optionable

IMAC, BACK, AIH, and PTPI Headlines

SourceHeadline
Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid HealthPetros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health
finance.yahoo.com - April 25 at 1:37 PM
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid HealthPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid Health
finanznachrichten.de - April 23 at 11:32 AM
Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid HealthPetros Pharmaceuticals Expands Online Distribution for Prescription STENDRA(R) (avanafil) Through New Agreement with Lemonaid Health
accesswire.com - April 23 at 9:15 AM
Positive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra DevelopmentsPositive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra Developments
markets.businessinsider.com - April 18 at 8:38 AM
Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%Petros Pharmaceuticals (NASDAQ:PTPI) Trading Down 2.1%
americanbankingnews.com - April 18 at 1:40 AM
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
accesswire.com - April 16 at 9:15 AM
Petros Pharmaceuticals Reports Positive Results in…Petros Pharmaceuticals Reports Positive Results in…
pharmiweb.com - April 2 at 11:16 AM
Petros Pharma Stock Down, Despite Positive Results For Stendra StudyPetros Pharma Stock Down, Despite Positive Results For Stendra Study
markets.businessinsider.com - April 2 at 11:16 AM
PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 2 at 10:04 AM
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC StatusPetros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
accesswire.com - April 2 at 9:15 AM
Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software ProviderPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
finanznachrichten.de - March 20 at 6:51 AM
Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software ProviderPetros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software Provider
accesswire.com - March 19 at 9:00 AM
Petros Pharmaceuticals Inc Ordinary Shares PTPIPetros Pharmaceuticals Inc Ordinary Shares PTPI
morningstar.com - March 6 at 6:19 PM
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
finance.yahoo.com - February 14 at 1:06 PM
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
accesswire.com - February 14 at 9:15 AM
Petros Pharmaceuticals Inc (PTPI)Petros Pharmaceuticals Inc (PTPI)
uk.investing.com - January 30 at 10:31 AM
Petros Pharmaceuticals Announces Two Upcoming FDA…Petros Pharmaceuticals Announces Two Upcoming FDA…
pharmiweb.com - January 24 at 2:25 PM
Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC SwitchPetros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC Switch
finance.yahoo.com - January 24 at 2:25 PM
Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC SwitchPetros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC Switch
finance.yahoo.com - January 17 at 10:12 AM
Buy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway ComplianceBuy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway Compliance
markets.businessinsider.com - December 14 at 12:30 PM
Petros Pharma Stock (NASDAQ:PTPI) Insider TradesPetros Pharma Stock (NASDAQ:PTPI) Insider Trades
benzinga.com - December 12 at 12:26 PM
Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology ProviderPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology Provider
finance.yahoo.com - December 12 at 12:26 PM
Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC StatusPetros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC Status
finance.yahoo.com - December 12 at 12:26 PM
Maxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy RecommendationMaxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy Recommendation
nasdaq.com - December 9 at 8:52 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Aesthetic Medical International Holdings Group logo

Aesthetic Medical International Holdings Group

NASDAQ:AIH
Aesthetic Medical International Holdings Group Limited provides aesthetic medical services in the People's Republic of China and Singapore. The company offers surgical aesthetic treatments, such as eye surgery, rhinoplasty, breast augmentation, and liposuction; and non-surgical aesthetic treatments, including minimally invasive and energy-based treatments, which include laser, ultrasound, and ultraviolet light treatments. It also provides general healthcare and other aesthetic medical services, such as internal medicine, urology, gynecology, and obstetrics treatment services, as well as dentistry, dermatology, and hair loss treatment services. The company was founded in 1997 and is headquartered in Shenzhen, the People's Republic of China.
IMAC logo

IMAC

NASDAQ:BACK
IMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
IMAC logo

IMAC

NASDAQ:IMAC
IMAC Holdings, Inc. owns, manages, and subleases a chain of innovative medical advancements and care regeneration centers in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides physical therapy and spinal decompression, and chiropractic manipulation. The company owns or manages 15 outpatient medical clinics in Kentucky, Missouri, Tennessee, Illinois, Louisiana, and Florida. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
Petros Pharmaceuticals logo

Petros Pharmaceuticals

NASDAQ:PTPI
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, PreBoost, VenoSeal, penile injections, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.